title: Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons.
abstract: OBJECTIVE
  To examine evidence for effectiveness of anteromesial temporal lobe and localized neocortical resections for disabling complex partial seizures by systematic review and analysis of the literature since 1990.
  
  
  RESULTS
  One intention-to-treat Class I randomized, controlled trial of surgery for mesial temporal lobe epilepsy found that 58% of patients randomized to be evaluated for surgical therapy (64% of those who received surgery) were free of disabling seizures and 10 to 15% were unimproved at the end of 1 year, compared with 8% free of disabling seizures in the group randomized to continued medical therapy. There was a significant improvement in quantitative quality-of-life scores and a trend toward better social function at the end of 1 year for patients in the surgical group, no surgical mortality, and infrequent morbidity. Twenty-four Class IV series of temporal lobe resections yielded essentially identical results. There are similar Class IV results for localized neocortical resections; no Class I or II studies are available.
  
  
  CONCLUSIONS
  A single Class I study and 24 Class IV studies indicate that the benefits of anteromesial temporal lobe resection for disabling complex partial seizures is greater than continued treatment with antiepileptic drugs, and the risks are at least comparable. For patients who are compromised by such seizures, referral to an epilepsy surgery center should be strongly considered. Further studies are needed to determine if neocortical seizures benefit from surgery, and whether early surgical intervention should be the treatment of choice for certain surgically remediable epileptic syndromes.
authors.affiliation: Neurological Research Center, Department of Neurology #1250, 710 Westwood Plaza, Los Angeles, CA 90095-1769, USA. engel@ucla.edu
authors.forename: J
authors.initials: J
authors.lastname: Engel
authors.forename: S
authors.initials: S
authors.lastname: Wiebe
authors.forename: J
authors.initials: J
authors.lastname: French
authors.forename: M
authors.initials: M
authors.lastname: Sperling
authors.forename: P
authors.initials: P
authors.lastname: Williamson
authors.forename: D
authors.initials: D
authors.lastname: Spencer
authors.forename: R
authors.initials: R
authors.lastname: Gumnit
authors.forename: C
authors.initials: C
authors.lastname: Zahn
authors.forename: E
authors.initials: E
authors.lastname: Westbrook
authors.forename: B
authors.initials: B
authors.lastname: Enos
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D002541:Cerebral Decortication / Q000009:adverse effects / Q000401:mortality / Q000592:standards; D004827:Epilepsy / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D019579:Neocortex / Q000601:surgery*; D017063:Outcome Assessment, Health Care / Q000706:statistics & numerical data*; D011183:Postoperative Complications / Q000209:etiology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018570:Risk Assessment; D013702:Temporal Lobe / Q000601:surgery*; D016896:Treatment Outcome; D014481:United States
chemical_list: D000927:Anticonvulsants